BRAF and colorectal carcinoma: For example, while MEKi (selumetinib, AZD6244) may mediate feedback activation of EGFR in BRAF (V600E) CRC cells [9], no clinical responses were observed in CRC patients treated with combination of MEKi with EGFRi [10].